Robert Wasserman
Stock Analyst at Benchmark
(3.72)
# 750
Out of 4,966 analysts
114
Total ratings
48.62%
Success rate
8.54%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.28 | +431.91% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $54.63 | +37.29% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $6.92 | +116.76% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.60 | +275.00% | 9 | May 12, 2025 | |
| ITGR Integer Holdings | Maintains: Buy | $150 → $140 | $107.87 | +29.79% | 11 | Apr 25, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $32.47 | +7.79% | 1 | Apr 17, 2025 | |
| IPA ImmunoPrecise Antibodies | Reiterates: Speculative Buy | $3 | $2.37 | +26.58% | 6 | Apr 1, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $4.18 | - | 6 | Mar 3, 2025 | |
| HALO Halozyme Therapeutics | Reiterates: Buy | $75 | $73.15 | +2.53% | 9 | Feb 20, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $25.05 | +19.76% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $8 | $2.50 | +220.00% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $3.73 | +34.05% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $8.30 | +44.58% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.73 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $122.32 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $49.81 | -9.66% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.94 | -19.03% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.19 | +2,016.40% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.58 | +2,806.98% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $205.82 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $492.72 | +17.71% | 1 | Jul 16, 2021 |
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.28
Upside: +431.91%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $54.63
Upside: +37.29%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $6.92
Upside: +116.76%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.60
Upside: +275.00%
Integer Holdings
Apr 25, 2025
Maintains: Buy
Price Target: $150 → $140
Current: $107.87
Upside: +29.79%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $32.47
Upside: +7.79%
ImmunoPrecise Antibodies
Apr 1, 2025
Reiterates: Speculative Buy
Price Target: $3
Current: $2.37
Upside: +26.58%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.18
Upside: -
Halozyme Therapeutics
Feb 20, 2025
Reiterates: Buy
Price Target: $75
Current: $73.15
Upside: +2.53%
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $25.05
Upside: +19.76%
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.50
Upside: +220.00%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $3.73
Upside: +34.05%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.30
Upside: +44.58%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.73
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $122.32
Upside: -
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $49.81
Upside: -9.66%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.94
Upside: -19.03%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.19
Upside: +2,016.40%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.58
Upside: +2,806.98%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $205.82
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $492.72
Upside: +17.71%